These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 6134697)
21. Secondary prevention after myocardial infarction: a review of short-term acute phase trials. May GS; Furberg CD; Eberlein KA; Geraci BJ Prog Cardiovasc Dis; 1983; 25(4):335-59. PubMed ID: 6129678 [No Abstract] [Full Text] [Related]
22. Secondary prevention of myocardial infarction. Davies JA Int J Clin Pharmacol Res; 1985; 5(5):303-7. PubMed ID: 3905632 [TBL] [Abstract][Full Text] [Related]
23. Secondary prevention after myocardial infarction: a review of long-term trials. May GS; Eberlein KA; Furberg CD; Passamani ER; DeMets DL Prog Cardiovasc Dis; 1982; 24(4):331-52. PubMed ID: 6119737 [No Abstract] [Full Text] [Related]
24. Modern drug treatment--No. 8. Drugs and the prevention of death from myocardial infarction. Graham IM Ir Med J; 1982 Aug; 75(8):291-6. PubMed ID: 6127329 [No Abstract] [Full Text] [Related]
25. [Secondary prevention after myocardial infarct]. Trenkwalder P; Lydtin H Dtsch Med Wochenschr; 1990 Oct; 115(40):1519-27. PubMed ID: 1976501 [No Abstract] [Full Text] [Related]
26. Long-term treatment after acute myocardial infarction: antiarrhythmic therapy and prophylaxis. Which drug for which patient? Bracchetti D; Naccarella F; Palmieri M; Fulvi M; Pavesi PC J Cardiovasc Pharmacol; 1989; 14 Suppl 9():S79-83. PubMed ID: 2483239 [TBL] [Abstract][Full Text] [Related]
27. E.P.S.I.M., the French oral anticoagulant--aspirin trial in post-myocardial infarction patients: design, organization and quality control procedures. Boissel JP; Leizorovicz A; Schbath J; Destors JM; Gillet J Scand J Haematol Suppl; 1981; 38():47-72. PubMed ID: 7038857 [No Abstract] [Full Text] [Related]
28. Secondary prevention trials after acute myocardial infarction. Furberg CD Am J Cardiol; 1987 Jul; 60(2):28A-32A. PubMed ID: 2887098 [TBL] [Abstract][Full Text] [Related]
29. [Secondary prevention of myocardial infarct with anti-arrhythmia drugs and beta receptor blockaders]. Mösslacher H Wien Med Wochenschr; 1984 Dec; 134(23-24):566-72. PubMed ID: 6152091 [TBL] [Abstract][Full Text] [Related]
30. [Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs]. Noll G; Kaufmann U; Wenzel RR; Lüscher TF Schweiz Med Wochenschr; 1996 Feb; 126(5):164-76. PubMed ID: 8685687 [TBL] [Abstract][Full Text] [Related]
31. [Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. Reikvam A; Madsen S; Landmark K Tidsskr Nor Laegeforen; 2003 Jun; 123(13-14):1838-40. PubMed ID: 12830258 [TBL] [Abstract][Full Text] [Related]
33. Beta-blockers in the secondary prevention of myocardial infarction: a review of clinical trials of 12 months or more duration. Decorde P Pharmatherapeutica; 1984; 3(8):515-25. PubMed ID: 6142464 [TBL] [Abstract][Full Text] [Related]
34. Interventions during and after acute myocardial infarction. Sleight P Postgrad Med J; 1983; 59 Suppl 3():80-8. PubMed ID: 6139802 [TBL] [Abstract][Full Text] [Related]
35. Clinical trials of platelet-active drugs in coronary heart disease: summary of design features. Furberg CD; May GS Circulation; 1980 Dec; 62(6 Pt 2):V49-52. PubMed ID: 7002352 [TBL] [Abstract][Full Text] [Related]
36. [Role of antiplatelet agents in the prevention of cerebral ischemic accidents]. Bousser MG J Mal Vasc; 1983; 8(1):17-22. PubMed ID: 6341494 [TBL] [Abstract][Full Text] [Related]
37. [Secondary prevention of myocardial infarction using anti-arrhythmia agents and beta-receptor blockers]. Mösslacher H Acta Med Austriaca; 1984; 11(1):1-8. PubMed ID: 6143463 [TBL] [Abstract][Full Text] [Related]
38. Secondary prevention after myocardial infarction: facts and fallacies. Taylor SH J Cardiovasc Pharmacol; 1984; 6 Suppl 6():S914-21. PubMed ID: 6084149 [TBL] [Abstract][Full Text] [Related]